Sensus Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined year-over-year due to loss of a major customer, but underlying growth was seen from a diversified base. New CPT codes and software initiatives are driving increased adoption, recurring revenue, and a positive outlook for sequential quarterly improvement in 2026.
Fiscal Year 2025
-
Exclusive CPT codes for SRT and IG-SRT provide reimbursement clarity, supporting broader adoption and international growth. 2025 saw lower revenues and a net loss, but a strong balance sheet and diversified customer base position the company for profitability in 2026.
-
Q3 2025 saw revenue and unit sales decline year-over-year, but new CMS reimbursement codes for SRT are expected to drive strong future demand and improve ROI for dermatology practices. The company maintains a strong cash position, anticipates international growth, and expects to reach break-even or profitability in Q4.
-
Q2 2025 saw a revenue decline due to paused domestic sales amid reimbursement uncertainty, but international demand grew and recurring revenue partially offset lower capital sales. Management expects resolution of reimbursement issues by year-end, with strong cash reserves and new market opportunities ahead.
-
Q1 2025 saw lower revenue and a net loss due to strategic investments, but recurring revenue from FDA agreements grew 65% sequentially. Profitability is expected to return in the next three quarters, with significant revenue contributions from FDA agreements anticipated in the second half of 2025.
Fiscal Year 2024
-
Revenue grew 71% year-over-year to $41.8M in 2024, with record SRT-100 system shipments and ongoing profitability. The Fair Deal Agreement program is expected to drive significant recurring revenue in the second half of 2025, while strong liquidity supports continued R&D and expansion.
-
Revenues more than doubled year-over-year in Q3 2024, driven by strong SRT system sales and a major Fair Deal Agreement with Platinum Dermatology Partners. Profitability was achieved despite seasonality, and recurring revenue from new agreements is expected to ramp up in 2025.
-
Q2 2024 saw revenue more than double year-over-year, driven by strong SRT system sales and the launch of the Fair Deal Agreement, with 15 contracts signed and up to 50 expected by year-end. Recurring revenue from these agreements will begin in 2025, and gross margin is projected to remain around 60%.